Valuation: Monte Rosa Therapeutics, Inc.

Market Cap 2.07B 1.81B 1.67B 1.54B 2.91B 200B 2.97B 20B 7.87B 97.86B 7.79B 7.62B 337B P/E 2026 *
-14.8x
P/E 2027 * -13.4x
Enterprise Value 2.07B 1.81B 1.67B 1.54B 2.91B 200B 2.97B 20B 7.87B 97.86B 7.79B 7.62B 337B EV / Sales 2026 *
46.6x
EV / Sales 2027 * 35.7x
Free-Float
99.42%
Yield 2026 *
-
Yield 2027 * -
1 day+6.04%
1 week+6.60%
Current month+1.49%
1 month+33.41%
3 months+24.17%
6 months+3.58%
Current year+56.63%
1 week 20.92
Extreme 20.925
24.71
1 month 17.91
Extreme 17.91
25.22
Current year 13.69
Extreme 13.69
25.77
1 year 4.12
Extreme 4.12
25.77
3 years 2.44
Extreme 2.44
25.77
5 years 2.44
Extreme 2.44
45.56
10 years 2.44
Extreme 2.44
45.56
Manager TitleAgeSince
Chief Executive Officer 55 01/01/2020
Chief Tech/Sci/R&D Officer - 17/03/2026
Chief Operating Officer 54 01/03/2021
Director TitleAgeSince
Director/Board Member 55 01/01/2020
Director/Board Member 49 01/04/2020
Director/Board Member 57 01/06/2020
Date Insider Type Main position Quantity % Market Cap.
7/15/26 A Fiscal year

Chief Operating Officer

13,053 0.0155%
7/6/26 A Fiscal year

Chief Technology Officer

18,000 0.0213%
7/1/26 A
NEA Management Co. LLC
OthersCompany -1,030,000 1.2192%
Change 5-day change 1-year change 3-year change Capi.($)
+6.04%+6.60%+316.27%+250.36% 2.07B
+3.90%-0.39%+376.72%+599.59% 39.58B
-1.70%+4.46%+7.46%+57.67% 34.69B
-2.01%-0.76%+26.35%-6.83% 34.42B
+0.06%+0.34%+2.32%+29.30% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+68.48%+117.39% 15.36B
+1.12%+1.91%+15.90%+19.65% 14.05B
0.00%+1.36%+15.74%-30.62% 13.02B
-0.08%-3.01%+1,271.69%+649.69% 11.76B
Average +0.78%+0.69%+233.44%+187.35% 20.83B
Weighted average by Cap. +0.30%+0.42%+173.00%+188.10%

Financials

2026 *2027 *
Net sales 44.48M 38.87M 35.87M 33.06M 62.31M 4.28B 63.7M 429M 169M 2.1B 167M 163M 7.22B 58.17M 50.84M 46.91M 43.24M 81.5M 5.6B 83.31M 561M 221M 2.74B 218M 214M 9.44B
Net income -167M -146M -135M -124M -234M -16.11B -240M -1.61B -634M -7.89B -628M -615M -27.16B -193M -169M -156M -144M -271M -18.63B -277M -1.87B -734M -9.13B -727M -711M -31.42B
Net Debt - -
Logo Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Employees
187
Date Price Change Volume
17/07/26 $24.56 +6.04% 1,220,500
16/07/26 $23.16 -1.07% 1,149,615
15/07/26 $23.41 -0.21% 842,627
14/07/26 $23.46 +6.73% 1,155,153
13/07/26 $21.98 -4.60% 1,586,861
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
24.56USD
Average target price
33.17USD
Spread / Average Target
+35.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLUE Stock